BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cumberland Pharmaceuticals Sets 6.25 Million Share IPO


7/24/2007 8:03:46 AM

NASHVILLE, Tenn., July 23 /PRNewswire/ -- Cumberland Pharmaceuticals today filed with the U.S. Securities and Exchange Commission an amendment to its registration statement for the proposed initial public offering of its common stock. The estimated price range for the initial public offering is $14.00 to $16.00 per share. Cumberland proposes to sell 6.25 million shares in the offering, and to grant the underwriters an option to purchase up to an additional 937,500 shares to cover over-allotments, if any. All of the shares of common stock will be offered by Cumberland.

UBS Investment Bank will serve as the sole book-running manager for the offering. Jefferies & Company, Wachovia Securities and Morgan Joseph will act as co-managers for the offering.

The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the offering may be obtained from the prospectus department of UBS Investment Bank, Attn: Prospectus Department, 299 Park Avenue, New York, New York 10171 (telephone number 212-821-3000).

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective.

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Cumberland's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote(R) for the treatment of acetaminophen poisoning and Kristalose(R), a prescription strength laxative. The Company is also developing Amelior(R) which is in Phase III studies for the treatment of both pain and fever. Cumberland is dedicated to providing innovative products which improve quality of care for patients.

Cumberland Pharmaceuticals

CONTACT: Rebecca Kirkham of Lovell Communications, +1-615-297-7766,Rebecca@Lovell.com, for Cumberland Pharmaceuticals



Read at Reuters

Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES